Ipamorelin

Ipamorelin (GH secretagogue) is a pentapeptide. The HEIVE catalog describes it as: A selective growth-hormone releasing peptide with little effect on cortisol or prolactin.

HEIVE groups Ipamorelin under fatigue, workout energy, sleep, metabolic health and bone density. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

No matching FDA product was identified for Ipamorelin under the searched names in the October 6, 2026 Drugs@FDA snapshot. This name search does not establish worldwide approval status or exclude differently named products. FDA describes safety concerns or insufficient safety information for the corresponding substance on its compounding-risk page; that listing is not a drug approval.

• FDA product data (October 6, 2026)
• FDA compounding safety information

The HEIVE editorial risk summary for Ipamorelin lists: Head-rush and hunger in the first 20 minutes; water retention. Longer-term concerns: Sustained GH elevation carries insulin-resistance risk over years. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

Ipamorelin has no single onset time established by this catalog. The editorial timeline starts with “Days 1–7”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for Ipamorelin: 200–300 mcg before bed, on an empty stomach. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies Ipamorelin as having human research. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists sublingual for Ipamorelin. A listed form is not evidence of an approved or effective treatment.

Preparation of Ipamorelin depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for Ipamorelin depends on the specific formulation (injectable and sublingual in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for Ipamorelin: Receptor desensitisation is real. Five days on, two off is the common pattern. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

Ipamorelin and Sermorelin share the catalog categories fatigue, sleep and metabolic health. Ipamorelin: A selective growth-hormone releasing peptide with little effect on cortisol or prolactin. Sermorelin: The shortest fragment of natural GHRH that still works. It was a licensed medicine with a paediatric safety record before it was withdrawn commercially. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View Sermorelin

The HEIVE editorial summary highlights: Gastric motility improved in studies designed to look only at GH. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.